Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.47 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MOK | Q9UQ07 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20908967 | 0.87 | SMN1; SMN2 (0.46) | JAK3HIF1AEPAS1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22353551 | 0.79 | NOS1 (0.42) | SMN1; SMN2ALDH1A1KMT2AMEN1PRKD3 | |
| SCHEMBL28423187 | 0.79 | ADORA2A (0.48) | SMN1; SMN2ALDH1A1KMT2AMEN1PRKD3 | |
| SCHEMBL22206182 | 0.79 | JAK3 (0.45) | JAK3ALDH1A1NPC1RAB9ALMNA | |
| SCHEMBL29838339 | 0.77 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL22206146 | 0.77 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1KMT2AMEN1L3MBTL1 | |
| SCHEMBL28419550 | 0.74 | EGFR (0.51) | JAK3HIF1AEPAS1SMN1; SMN2ALDH1A1 | |
| SCHEMBL20908748 | 0.73 | EGFR (0.50) | JAK3EGFRAURKAJAK2 | |
| SCHEMBL20908837 | 0.73 | EGFR (0.50) | JAK3MOKEGFRAURKAJAK2 | |
| SCHEMBL20908961 | 0.73 | ACKR3 (0.51) | JAK3EGFRJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3696176-B1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | DAE WOONG PHARMA (KR) | 2022-05-04 | — | — | EP | disclosed |
| US-11149019-B2 | Phenylpyridine derivative and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-10-19 | — | — | US | disclosed |
| EP-3696176-A1 | NOVEL PHENYLPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Daewoong Pharmaceutical Co., Ltd. (KR) | 2020-08-19 | — | — | EP | disclosed |
| US-20200223821-A1 | Novel Phenylpyridine Derivative and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223821-A1 | Novel Phenylpyridine Derivative and Pharmaceutical Composition Comprising the Same | PDCD1, PDCD5, PDCD11 | JAK3 811/4885HIF1A 2503/4885EPAS1 544/4885 |
| US-11149019-B2 | Phenylpyridine derivative and pharmaceutical composition comprising the same | DPYD, PDCD5, PDCD1 | JAK3 869/4885HIF1A 2331/4885EPAS1 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.